The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Some practical improvements in the continual reassessment method for phase I studies
Abstract
The Continual Reassessment Method (CRM) is a Bayesian phase I design whose purpose is to estimate the maximum tolerated dose of a drug that will be used in subsequent phase II and III studies. Its acceptance has been hindered by the greater duration of CRM designs compared to standard methods, as well as by concerns with excessive experimentation at high dosage levels, and with more frequent and severe toxicity. This paper presents the results of a simulation study in which one assigns more than one subject at a time to each dose level, and each dose increase is limited to one level. We show that these modifications address all of the most serious criticisms of the CRM, reducing the duration of the trial by 50–67 per cent, reducing toxicity incidence by 20–35 per cent, and lowering toxicity severity. These are achieved with minimal effects on accuracy. Most important, based on our experience at our institution, such modifications make the CRM acceptable to clinical investigators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
A comparison of two phase I trial designs
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C., & Simon, R. M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131802 · Cited by 303
O'Quigley, J., & Chevret, S. (1991) · Statistics in Medicine · doi:10.1002/sim.4780101104 · Cited by 179
Cited by
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.106 · Cited by 434
Bayesian methods in health technology assessment: a review.
Spiegelhalter, Myles, Jones, & Abrams (2000) · Health Technology Assessment · doi:10.3310/hta4380 · Cited by 358
Metadata
- Authors
- Goodman, S. N., Zahurak, M. L., & Piantadosi, S.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 1995-06-15
- Volume
- 14
- Issue
- 11
- Pages
- 1149-1161
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2158740848
- Cited by
- 472
- References
- 4
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Some practical improvements in the continual reassessment method for phase I studies. https://app.cochat.ai/papers/10.1002/sim.4780141102
- The paper
- Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine. https://doi.org/10.1002/sim.4780141102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.